Cue Biopharma Reports Third Quarter 2024 Financial Results and Recent Business Highlights
Provided By GlobeNewswire
Last update: Nov 14, 2024
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively engage and modulate disease-specific T cells for the treatment of cancer and autoimmune disease, today provided a business and financial update for the third quarter of 2024.
Read more at globenewswire.comNASDAQ:CUE (7/11/2025, 8:02:23 PM)
0.766
-0.03 (-3.77%)
Find more stocks in the Stock Screener
CUE Latest News and Analysis
11 days ago - ChartmillWhat's going on in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Tuesday. Below you can find the top gainers and losers in today's after hours session.
